Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
4
×
life sciences
national blog main
new york blog main
san diego blog main
4
×
san francisco
4
×
san francisco blog main
4
×
san francisco top stories
biotech
boston blog main
boston top stories
national top stories
new york top stories
san diego top stories
startups
cancer
gene therapy
raleigh-durham blog main
seattle blog main
seattle top stories
vc
10x genomics
accelerator
acetylon pharmaceuticals
adeno-associated virus
airbnb
alexandria venture investments
altitude life science ventures
amazon web services (aws)
ambys medicines
american society of gene and cell therapy
arch venture partners
artificial intelligence (a.i.)
astellas pharma
athelas
atomwise
becton dickinson
benchling
biotechnology
boxer capital
What
big
deal
help
make
startup
treatment
adding
admits
ago
aiming
aims
ambys
biotech
biotechs
classes
combinator
companies
company
control
crude
cutting
deadly
debuted
decisions
despite
diagnostic
diagnostics
diseases
dug
edge
effects
encoded
expand
fold
formed
future
gene
illumina’s
incubator
lasting
Language
unset
Current search:
deals
×
" san francisco blog main "
×
" san francisco "
×
" san diego blog main "
×
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
